← All trials
NCT07118800
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2025
- Primary completion
- Dec 15, 2030
- Completion date
- Jan 15, 2032
- First posted
- Aug 12, 2025
- Last posted
- Aug 12, 2025
- Enrollment
- 160
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UNICANCERLead sponsor
- University of Nice Sophia AntipolisOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.